Short-term rapamycin for inhibition of neointima formation after balloon-mediated aortic injury in rats: Is there a window of opportunity for systemic prophylaxis of restenosis?

Journal of Endovascular Therapy

Volumn 12, Issue 3, 2005, Pages 332-342

  Jahnke, Thomas ^a   Schäfer, Fritz K W ^a   Boite, Hendrik ^a   Heuer, Gerrit ^a   Karbe, Ulf ^a   Brossmann, Joachim ^a   Brandt, Michael ^b   Heller, Martin ^a   Müller Hülsbeck, Stefan ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Municipal Hospital Rendsburg   (Germany)

Author keywords

Angioplasty; Balloon injury model; Neointimal hyperplasia; Rapamycin; Rat model; Restenosis

Indexed keywords

ALPHA ACTIN; RAPAMYCIN;

ADVENTITIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; BODY WEIGHT; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESTENOSIS; SHORT COURSE THERAPY; WEIGHT REDUCTION;

ACTINS; ANGIOPLASTY, BALLOON; ANIMALS; AORTA, ABDOMINAL; ARTERIAL OCCLUSIVE DISEASES; CELL COUNT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, INBRED LEW; RECURRENCE; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 20444441504     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/04-1498R.1     Document Type: Article

References (52)

1. Morgenstern BR, Getrajdman GI, Laffey KJ, et al. Total occlusion of the femoropopliteal artery, high technical success rate of conventional balloon angioplasty. Radiology. 1998;172: 937-940.
2. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: have we been aiming at the wrong target? J Am Coll Cardiol. 1995;25:516-520.
3. Hintner M, Behrmann C. Long-term results of angioplasties of pelvic and leg blood vessels [in German]. Rofo. 2000;172:775-779.
4. Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation. 1994;89:2888-2889.
5. Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 1997;95: 1998-2002.
6. Barth KH, Virmani R, Froelich J, et al. Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and Wallstents in canine iliac and femoral arteries. Circulation. 1996;93:2161-2169.
7. Lafont A, Topol E, eds. Arterial Remodeling: A Critical Factor in Restenosis. Boston: Kluwer Academic Publishers; 1997.
8. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol. 1995;25:362-369.
9. Kastrati A, Schuhlen H, Hausleiter J, et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation. 1997;96:462-467.
10. Bertrand ME, McFadden EP, Fruchart JC, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J Am Coll Cardiol. 1997;30:863-869.
11. Boccuzzi SJ, Weintraub WS, Kosinski AS, et al. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). Am J Cardiol. 1998;81:632-636.
12. Serruys PW, Foley DP, Hofling B, et al. Carvedilol for prevention of restenosis after directional coronary atherectomy: final results of the European carvedilol atherectomy restenosis (EUROCARE) trial. Circulation. 2000;101:1512-1518.
13. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-1193.
14. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104: 473-479.
15. Virmani R, Farb A, Guagliumi G, et al. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis. 2004;15:313-318.
16. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation. 2002;105:1883-1886.
17. Fändrich F, Ruhnke M, Dresske B, et al. Tolerance-inducing strategies in transplantation surgery-current status and perspectives. Langenbecks Arch Surg. 2004;389:60-66.
18. Jahnke T, Karbe U, Schäfer FK, et al. Characterization of a new double-injury restenosis model in the rat aorta. J Endovasc Ther. 2005;12:318-331.
19. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984;32:219-229.
20. Capron L, Jarnet J, Heudes D, et al. Repeated balloon injury of rat aorta. Arterioscler Thromb Vasc Biol. 1997;17:1649-1656.
21. Foegh M, Virmani R. Molecular biology of intimal proliferation. Curr Opin Cardiol. 1993;8: 938-955.
22. Gorski DH, LePage DF, Patel CV, et al. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol. 1993;13:3722-3733.
23. Casscells W, Lappi DA, Baird A. Molecular atherectomy for restenosis. Trends Cardiovasc Med. 1993;3:235.
24. Lafont A, Faxon D. Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res. 1998;39:50-59.
25. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
26. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002;106: 2649-2651.
27. Faxon DP. Systemic drug therapy for restenosis: "déjà vu all over again." Circulation. 2002;106:2296-2298.
28. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28:721-726.
29. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28:727-732.
30. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108: 48-53.
31. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335-340.
32. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283.
33. Burke SE, Lubbers NL, Chen YW, et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol. 1999;33: 829-835.
34. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimai thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99:2164-2167.
35. Hirosumi J, Nomoto A, Ohkubo Y, et al. Inflammatory responses in cuff-induced atherosclerosis in rabbits. Atherosclerosis. 1987;64:243-254.
36. Moroi M, Zhang L, Yasuda T, et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998;101:1225-1232.
37. Akishita M, Horiuchi M, Yamada H, et al. Inflammation influences vascular remodeling through AT2 receptor expression and signalling. Physiol Genomics. 2000;2:13-20.
38. Wu L, Iwai M, Nakagami H, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type I receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001;104:2716-2721.
39. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
40. Farb A, John M, Acampado E, et al. Oral everolimus inhibits in-stent neointimal growth. Circulation. 2002;106:2379-2384.
41. Uchimura N, Perera GB, Fujitani RM, et al. Dose-dependent inhibition of myointimal hyperplasia by orally administered rapamycin. Ann Vasc Surg. 2004;18:172-177.
42. Brara PS, Moussavian M, Grise MA, et al. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation. 2003;107:1722-1724.
43. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis. The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004;110:790-795.
44. Rodriguez AE, Alemparte MR, Vigo CF, et al. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy. Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol. 2003;15:581-584.
45. Waksman R, Ajani AE, Pichard AD, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol. 2004;44:1386-1392.
46. Li G, Chen SJ, Oparil S, et al. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation. 2000;101:1362-1365.
47. Oparil S, Chen SJ, Chen YF, et al. Estrogen attenuates the adventitial contribution to neointimal formation in injured rat carotid arteries. Cardiovasc Res. 1999;44:608-614.
48. Bayes-Genis A, Kantor B, Keelan PC, et al. Restenosis and hyperplasia: animal models. Curr Interv Cardiol Rep. 2000;2:303-308.
49. Herreia VL, Makrides SC, Xie HX, et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med. 1999;5:1383-1389.
50. Finn AV, Gold HK, Tang A, et al. A novel rat model of carotid artery stenting for the understanding of restenosis in metabolic disease. J Vasc Res. 2002;39:414-425.
51. Leidenfrost JE, Khan MF, Boc KP, et al. A model of primary atherosclerosis and post-angioplasty restenosis in mice. Am J Pathol. 2003;163: 773-778.
52. Von der Thusen JH, Fekkes ML, Passier R, et al. Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis. Arterioscler Thromb Vasc Biol. 2004;24:357-362.